Cwm LLC Sells 2,158 Shares of Illumina, Inc. (NASDAQ:ILMN)

Cwm LLC cut its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 3.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 64,217 shares of the life sciences company’s stock after selling 2,158 shares during the quarter. Cwm LLC’s holdings in Illumina were worth $8,942,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in the stock. Vanguard Group Inc. increased its stake in Illumina by 15.0% in the third quarter. Vanguard Group Inc. now owns 17,967,758 shares of the life sciences company’s stock valued at $2,466,614,000 after acquiring an additional 2,336,935 shares during the last quarter. Barclays PLC raised its holdings in shares of Illumina by 120.0% during the 3rd quarter. Barclays PLC now owns 1,768,355 shares of the life sciences company’s stock valued at $242,758,000 after buying an additional 964,709 shares in the last quarter. abrdn plc lifted its position in Illumina by 764.9% in the 4th quarter. abrdn plc now owns 339,023 shares of the life sciences company’s stock worth $47,206,000 after buying an additional 299,827 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its stake in Illumina by 245.7% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 417,876 shares of the life sciences company’s stock worth $57,366,000 after buying an additional 296,990 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its position in Illumina by 6.6% during the third quarter. Bank of New York Mellon Corp now owns 3,648,935 shares of the life sciences company’s stock valued at $500,926,000 after acquiring an additional 225,074 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Stock Performance

NASDAQ ILMN opened at $120.25 on Tuesday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.29 and a current ratio of 1.66. Illumina, Inc. has a 12 month low of $89.00 and a 12 month high of $229.58. The company’s 50 day moving average is $132.98 and its two-hundred day moving average is $127.68.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, February 8th. The life sciences company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.13. The business had revenue of $1.12 billion for the quarter, compared to analysts’ expectations of $1.09 billion. Illumina had a positive return on equity of 2.20% and a negative net margin of 25.78%. The business’s quarterly revenue was up 3.6% on a year-over-year basis. During the same period last year, the firm earned $0.14 earnings per share. As a group, equities research analysts expect that Illumina, Inc. will post 0.91 EPS for the current fiscal year.

Insider Activity

In other news, CEO Jacob Thaysen purchased 7,330 shares of the company’s stock in a transaction that occurred on Thursday, February 22nd. The stock was bought at an average cost of $135.29 per share, with a total value of $991,675.70. Following the completion of the purchase, the chief executive officer now owns 14,861 shares in the company, valued at $2,010,544.69. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.17% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Barclays upped their price objective on shares of Illumina from $85.00 to $100.00 and gave the company an “underweight” rating in a research note on Wednesday, April 10th. OTR Global restated a “mixed” rating on shares of Illumina in a research report on Wednesday, March 20th. StockNews.com raised Illumina from a “hold” rating to a “buy” rating in a research note on Friday, February 16th. TD Cowen lowered Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 price target on the stock. in a research report on Thursday, January 4th. Finally, Stephens reissued an “overweight” rating and set a $170.00 price objective on shares of Illumina in a research note on Wednesday, April 10th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, Illumina presently has an average rating of “Hold” and an average target price of $167.70.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.